ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
Pharmacokinetics and Paw Withdraw Pressure in Guinea Pigs (Cavia porcellus) Treated with Transdermal Buprenorphine.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of effective analgesia is a cornerstone of laboratory animal care, one that minimizes pain and distress while optimizing care and welfare. Guinea pigs are often used in biomedical research requiring appropriate pain management. In this study, we evaluated the pharmacokinetics and efficacy of transdermal buprenorphine (Zorbium), a commercial product labeled for use in cats. Guinea pigs (n = 12) received a transdermal dose of buprenorphine (2.7 mg per guinea pig), an average dose of 3.4 mg/kg, applied topically to the interscapular area. Plasma concentration, paw withdraw pressure (PWP) response, sedation scores, and body temperature were collected at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, and 120 hours after application. Plasma concentrations peaked at 77.8 ng/mL at 1 hour and remained greater than the targeted 1.0 ng/mL for up to 120 hours, with a half-life of 46.7 hours. PWP peaked at 24 hours with 671.2 g of pressure, remained elevated through 48 hours at 364 g, and returned to baseline by 72 hours. Sedation scores (posture, ambulation, resistance to handling) were slightly elevated at 12 hours, body weight did not significantly change, and rectal temperatures remained normal at all time points. These results suggest that transdermal buprenorphine maintains a prolonged therapeutic plasma level and is an effective analgesic for up to 48 hours in guinea pigs, with minimal side effects. This formulation is an alternative to other buprenorphine formulations that would require less handling for guinea pigs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.